The three cannabidiol creams will be sold under the company’s First & Free brand. Canada-based Canopy Growth (NYSE:CGC) is expanding its brand footprint in the U.S. The cannabis company announced Monday that it’s rolling out the first line of topical products within its First & Free cannabidiol (CBD) brand. Its three new creams — Everyday,…
Canada-based Canopy Development( NYSE: CGC) is broadening its brand footprint in the U.S. The cannabis company revealed Monday that it’s presenting the very first line of topical products within its First & Free cannabidiol (CBD) brand name.
Its three brand-new creams– Daily, Movement, and Revitalize– are each loaded with 2,500 milligrams of CBD per 1.76- ounce tube. Canopy Development (citing details from Brightfield Research Group) says that makes them the greatest strength CBD topical creams sold in the U.S., with over five times the concentration of competing topicals.
Image source: Getty Images.
First & Free is the cannabis business‘s U.S.-exclusive CBD line of product. It was launched in December, almost one year after the 2018 Farm Bill legalized items made from hemp and CBD, a non-psychoactive substance found within the plant that is supposed to have medical residential or commercial properties. Following legalization, a market quickly sprang up throughout the nation for CBD items.
” With our new line of topical creams, First & Free is constructing a portfolio to treat the daily stress factors that affect both mind and body,” Canopy Development stated in a press release. The creams are offered online with two-day shipping. Each retails for $3999 per tube.
Image source: First & Free (Canopy Growth).
Although CBD product manufacturers consistently tout the health advantages of their wares, regulators have a less passionate view. Last year, the Fda released a customer upgrade on the substance in which it kept in mind that ” there is extremely minimal offered information about CBD, consisting of about its results on the body.”
Canopy Growth stock was trading up by 0.5%in mid-afternoon trading on Monday, while the wider equities market as determined by the S&P 500 was down by about 1.2%.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.”> Eric Volkman has no
position in any of the stocks discussed. The Motley Fool has no position in any of the stocks pointed out. The Motley Fool has a disclosure policy“>